The innovation that will change the future of medicine and health care as we know it will be a $6 billion industry by 2021. That’s not so far away. Join me as guest Sam de Brouwer, founder of Doc.AI discusses her innovations in artificial intelligence and the greater access she is creating for medical treatment; and guest Melanie Matheu, founder of Prellis Biologics as she discusses how new advances in tissue engineering could one day make a replacement liver from a patient’s cells. Science is fascinating and the entpreneurer’s journeys that these two take are inspiring. Join us! Sam is cofounder at doc.ai, Palo Alto CA and serves as Chief Community Officer. Before that she cofounded Scanadu Inc. in 2011 and served as its VP of communications until 2016. Scanadu is a venture backed company developing consumer facing mobile medical devices. Indiegogo crowdfunding campaign for a medical device ( $1.6 million ) shipped, and kicked off the largest remote clinical study with Scripps Translational Science Institute for 4000 people in the US and 7000 worldwide. Sam started her entrepreneurial career in 1996 with the Starlab research lab where she ran the business development department. It was her first experience with the MIT MediaLab, which specialized in blue sky research deep future research, and BANG (Bits, Atoms, Neurons and Genes) research. Starlab produced generic patents that were later sold to Philips. Learn more at http://www.tedxsanfrancisco.com/sam-de-brouwer and at www.doc.ai Dr. Matheu co-founder of Prellis Biologics, recently completed a postdoctoral scholar position at UC San Francisco, after which she moved on to local biotech start-up as an associate director tasked with developing immunological applications around novel technology. Dr. Matheu has over fourteen years of experience imaging single cell dynamics in whole tissues. Her research was dedicated to defining cell-cell communication patterns in living tissues, and changes in cell-cell interactions during an immune response. Dr. Matheu’s passion for understanding cell-cell interactions and her expertise in laser technology sparked her interest in de-novo tissue construction, leading her to found Prellis Biologics in the Fall of 2016. Learn more at http://www.prellisbio.com/ and on LinkedIn at https://www.linkedin.com/in/melaniematheu.